Eddie Hickman
Stock Analyst at Guggenheim
(4.25)
# 1,489
Out of 5,144 analysts
52
Total ratings
56.2%
Success rate
18.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GHRS GH Research | Reiterated: Buy | $40 → $46 | $19.93 | +130.81% | 6 | Nov 18, 2026 | |
| PMN ProMIS Neurosciences | Reiterated: Buy | $100 | $3.52 | +2,740.91% | 9 | Nov 16, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | $23 → $18 | $11.17 | +61.15% | 11 | Nov 16, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $89 → $97 | $69.07 | +40.44% | 17 | Nov 5, 2026 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.4621 | n/a | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $29.90 | n/a | 2 | Aug 11, 2025 |
GH Research
Nov 18, 2026
Reiterated: Buy
Price Target: $40 → $46
Current: $19.93
Upside: +130.81%
ProMIS Neurosciences
Nov 16, 2026
Reiterated: Buy
Price Target: $100
Current: $3.52
Upside: +2,740.91%
Zevra Therapeutics
Nov 16, 2026
Maintained: Buy
Price Target: $23 → $18
Current: $11.17
Upside: +61.15%
Tarsus Pharmaceuticals
Nov 5, 2026
Reiterated: Buy
Price Target: $89 → $97
Current: $69.07
Upside: +40.44%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.4621
Upside: n/a
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $29.90
Upside: n/a